GlassScriptPhysician profile
Danielle Rene Dunyo
NPI 1962166959
$15,153.41
in general payments reported to CMS, 2019-2025
29 companies · $5,033 in 2025
The $5,033 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,688 · 2023: $3,522 · 2024: $4,910 · 2025: $5,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,288 · Education: $78.83 · Travel and Lodging: $22.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,076.13 |
| Consulting Fee | $1,287.50 |
| Education | $78.83 |
| Travel and Lodging | $22.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,321.27 | 2022-2025 | |
| Corium, LLC | $2,130.27 | 2022-2025 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,666.57 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,098.07 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $985.38 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $974.79 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $764.34 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $712.69 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $681.21 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $566.38 | 2022-2025 | Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $479.15 | 2025 | Rejoyn |
| E.R. Squibb & Sons, L.L.C. | $394.87 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $364.27 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $276.99 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $274.76 | 2022-2025 | Trintellix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $240.35 | 2022-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $224.66 | 2022 | |
| Tris Pharma INC | $219.82 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $219.77 | 2022-2024 | Jornay Pm |
| Livanova USA, INC. | $99.78 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Merck Sharp & Dohme LLC | $91.64 | 2022-2023 | Belsomra |
| Almatica Pharma LLC | $91.64 | 2022-2025 | Loreev Xr |
| Bausch Health US, LLC | $82.64 | 2023-2025 | Aplenzin |
| Neos Therapeutics, LP | $45.39 | 2022-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $43.68 | 2025 | Jornay Pm |
| Indivior INC. | $35.22 | 2023-2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $29.79 | 2023 | Quviviq |
| Luye Pharma (USA) LTD. | $22.49 | 2025 | Erzofri Extended-Release |
| Sage Therapeutics, LLC | $15.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Dunyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.